STOCK TITAN

Biodexa Pharmaceuticals plc American Depositary Shs - $BDRX STOCK NEWS

Welcome to our dedicated page for Biodexa Pharmaceuticals plc American Depositary Shs news (Ticker: $BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals plc American Depositary Shs stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodexa Pharmaceuticals plc American Depositary Shs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodexa Pharmaceuticals plc American Depositary Shs's position in the market.

Rhea-AI Summary
Biodexa Pharmaceuticals has been granted an exception until July 18, 2023 to demonstrate compliance with Nasdaq's Minimum Bid Price Rule. If the securities fail to regain compliance by that date, they will be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.19%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.22%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
-
Rhea-AI Summary
Biodexa Pharmaceuticals announces that all resolutions put to the Company's shareholders were duly passed at the Annual General Meeting and General Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
none
Rhea-AI Summary
Biodexa Pharmaceuticals PLC has closed its registered direct offering, raising approximately $2.61 million. The company sold 22,135,922 new American Depositary Shares (ADSs) at a price of $0.15 per ADS. The net proceeds will be used for working capital and general corporate purposes. With this funding, Biodexa is expected to have sufficient cash resources to fund operations into Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Biodexa Pharmaceuticals PLC announces a registered direct offering of US$3.32 million, with the aim of raising funds for working capital and general corporate purposes. The offering is expected to close on May 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.31%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Rhea-AI Summary
Biodexa Pharmaceuticals has signed a non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, a precision oncology company. VarianBio is developing a high-potency aPKCi inhibitor for the treatment of various cancers. The proposed acquisition will involve the exchange of 10MM ADSs as initial consideration, with the potential for an additional 6MM ADSs based on milestones. Biodexa plans to raise at least US$7.0MM to fund VAR-101 through its Phase I proof-of-concept study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
Biodexa Pharmaceuticals plc American Depositary Shs

Nasdaq:BDRX

BDRX Rankings

BDRX Stock Data

4.06M
106.44M
10.26%
19.54%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Abingdon

About BDRX

midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b